A look into stent-related thrombus-burden: Bivalirudin versus heparin

Editorial commentary published in Catheterization and Cardiovascular Interventions (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Research reportEnsayos clínicosDesarrollo de fármacosRajagopalan P et al. · Catheterization and Cardiovascular Interventions, 2020

Abstract

Use of optical coherence tomography (OCT) adds an assessment of thrombus burden remaining on stents after PCI for acute coronary syndromes. Potential variations in stent-related thrombus burden can be documented by OCT as a function of peri-procedural pharmacology supporting the use of OCT in future hypothesis testing. Bivalirudin remains a reliable and expensive alternative to heparin in cases of HIT or patients at high bleeding risk during transfemoral PCI.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEditorialComment

Indexed MeSH termsHeparinHirudinsHumansPeptide FragmentsPercutaneous Coronary InterventionRecombinant ProteinsStentsThrombosisTomography, Optical CoherenceTreatment Outcome

Resumen

Editorial commentary discussing OCT-based assessment of residual stent-thrombus burden after PCI with bivalirudin vs heparin, supporting bivalirudin as an alternative in HIT and high-bleed-risk populations.

Por qué esto importa para la hirudoterapia

This article discusses optical coherence tomography (OCT) assessment of thrombus burden remaining on stents after percutaneous coronary intervention for acute coronary syndromes, noting that variations in stent-related thrombus burden can be documented as a function of peri-procedural pharmacology. It states that bivalirudin remains a reliable and expensive alternative to heparin in cases of heparin-induced thrombocytopenia or high bleeding risk during transfemoral PCI. Its relevance to ASH is indirect at most: the abstract does not describe bivalirudin as leech-derived, synthetic, or modeled on hirudin, and does not discuss leeches, hirudotherapy, or the leech secretome. The connection to ASH is therefore limited and not established by the abstract itself.

Citación

A look into stent-related thrombus-burden: Bivalirudin versus heparin.

Rajagopalan P et al. · Catheterization and Cardiovascular Interventions, 2020

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Clinical Evidence Clinical Applications Drug Pipeline Drug Development Direct Thrombin Inhibitors Hirudin Anticoagulation Compounds Bivalirudin Ecology & Conservation Otolaryngology Post-Thrombotic Syndrome Hemostasis

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026